Sodium dichloroacetate

Drug Profile

Sodium dichloroacetate

Alternative Names: Ceresine; CPC-211

Latest Information Update: 13 Oct 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Michigan State University
  • Developer Questcor Pharmaceuticals
  • Class Acetates; Antineoplastics; Nootropics; Small molecules
  • Mechanism of Action Pyruvate dehydrogenase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Craniocerebral trauma; Lactic acidosis; Spinal cord injuries; Stroke

Most Recent Events

  • 13 Oct 2005 Discontinued - Clinical-Phase-Unknown for Lactic acidosis in USA (unspecified route)
  • 13 Oct 2005 Discontinued - Phase-I for Head injuries in USA (IV)
  • 13 Oct 2005 Discontinued - Phase-I for Head injuries in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top